What smart money is saying about RxSight
1 fund in our archive has pitched RxSight, most recently Artisan Non US Small Mid Growth Strategy in June 2025.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Get an email when a fund buys, sells or pitches it
Position history
Every position in RxSight on record in the archive was reported in Q2 2025, across 1 fund letter, with 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2025 | 1 | 0 | 1 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- June 2025
“On an individual company basis, RxSight, BeOne Medicines and Edgewise Therapeutics were the largest Q2 detractors. RxSight has developed the Light Adjustable Lens™ (LAL), the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. This technology delivers the closest proximity to the natural eye’s accommodative vision, i.e., the eye’s ability to automatically adjust its focus to objects at different distances. Not only has RxSight’s current product launched strongly, but its platform technology can replicate close to 20/20 vision. The business, which has had a period of hyper growth, has lately faced a perfect storm, including the following: 1) increased competition from larger players, such as Johnson & Johnson and Alcon, which have aggressively bundled and discounted similar, but what we think are inferior, products; 2) a slowdown in discretionary spending that has hurt the premium- priced IOL market; and 3) a slower-than-anticipated launch of its LAL+ product extension. We believe these issues are transient, and the company will demonstrate its value going forward. Adhering to our price discipline, we have trimmed our position over the past two years as the share price rose almost 4X.”
RxSight
Fund coverage · 1 thesis
RxSight is a company with innovative adjustable intraocular lens technology that has faced recent challenges but is expected to demonstrate long-term value.
Read the full thesis
Read every full thesis on RxSight
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→